ArticleFrontiers in cell and developmental biology2026
Tumor-associated osteoclasts converge on a matrix-sulfation program across human bone tumors.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoclasts mediate the bone destruction that drives much of the morbidity of giant-cell tumor of bone, osteosarcoma, and skeletal metastasis, yet these large multinucleated cells are lost in droplet single-cell data and have never been defined as a disease cell state. Methods: We reanalyzed 378,936 cells from osteoclast-rich human bone tumors and reference datasets, using within-tumor comparisons and independent validation analyses to characterize shared osteoclast transcriptional programs across the three tumor classes. Results: Tumor osteoclasts from all three tumor classes converged on a shared 74-gene transcriptional program. The program showed high scores in osteoclasts and low scores in neighboring myeloid cells, reproduced across four cancers of origin and in an independent cohort of 38,361 osteoclasts, and centered on a glycosaminoglycan-sulfation and mineralization module comprising PAPSS2, UST, EXT1, and FAM20C. The enrichment held across donors, the program increased as human monocytes differentiated into osteoclasts, and it tracked mature-osteoclast abundance in an independent spatial cohort of human osteosarcoma. Osteoclasts expressing the program were associated with a collagen and CD44 signaling neighborhood, retained the canonical regulators PU.1, MITF, and NFATc1, and occupied the terminus of osteoclastogenesis. Discussion: Across biologically distinct bone cancers, tumor osteoclasts share a reproducible, maturation-associated state centered on matrix-sulfation biology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.